Anika Therapeutics (ANIK) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.42 +1.56%
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $26.17 million versus the consensus estimate of $28.13 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
